Co-Diagnostics partners with ReadyGo on blood-based testing

Salt Lake City, November 9, 2026 - Co-Diagnostics, Inc., a company listed on the NASDAQ under the ticker symbol CODX, has announced a partnership with ReadyGo Diagnostics Ltd. The purpose of this collaboration is to explore the potential of blood-based molecular testing technology, specifically for the early detection of Ebola virus.

The companies are testing whether ReadyGo’s GoCollect device, which prepares blood samples for molecular testing, can be utilized with Co-Diagnostics’ Co-Dx PCR platform, which currently handles swab-based testing. The Co-Dx PCR platform has not yet received FDA clearance or authorization.

The main focus of this joint venture is to determine if the technologies can be integrated into a single workflow that prepares blood samples, detects viruses, and aids in outbreak response. Co-Diagnostics, the CEO of which is Dwight Egan, stated that their primary goal is to make molecular testing accessible to patients in locations where laboratory infrastructure is scarce.

The ability to easily prepare blood samples under such conditions is seen as crucial, and ReadyGo’s technology could potentially aid in achieving this goal.

ReadyGo’s GoCollect technology specializes in preparing capillary blood samples for molecular testing. It uses integrated sample-conditioning chemistry and plasma separation, and importantly, it is designed to inactivate viruses at the point of collection. The compatibility between Co-Diagnostics’ and ReadyGo’s technologies is not yet confirmed, as the companies are currently conducting a feasibility study.

There are no guarantees that this evaluation will lead to a commercially available product, as it is still an ongoing process.

Should the evaluation prove successful, the collaboration could expand the Co-Dx PCR platform’s capabilities beyond swab-based testing to include the screening for other bloodborne pathogens, such as HIV and hepatitis B and C. However, each potential new application would necessitate separate development, validation, and regulatory authorization.

It is worth noting that as of September 7, 2026, the World Health Organization had reported 6,757 confirmed Ebola cases and 3,267 deaths in the ongoing outbreak in the Democratic Republic of the Congo. The Co-Diagnostics company recently held a press conference and webcast to provide further details about this exciting collaboration.